表紙
市場調査レポート

癌遺伝子阻害剤の市場およびパイプラインの分析:2015年

Oncogene Inhibitors Therapy Market & Pipeline Insight 2015

発行 KuicK Research 商品コード 327759
出版日 ページ情報 英文 500 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
癌遺伝子阻害剤の市場およびパイプラインの分析:2015年 Oncogene Inhibitors Therapy Market & Pipeline Insight 2015
出版日: 2015年04月03日 ページ情報: 英文 500 Pages
概要

癌遺伝子阻害剤の市場は急速な発展を遂げており、多くの製品が臨床パイプラインの各段階にあり、また多くの上市済み製品が産業ライフサイクルの各段階に存在しています。大規模な患者基盤と優れた技術がこの市場の持続的成長を支える重要な要因となっており、また、R&Dへの大規模な投資も市場成長に大きく貢献しています。

当レポートでは、癌遺伝子阻害剤の市場およびパイプラインの動向について調査し、癌遺伝子阻害剤の概要、機序、成長推進因子と課題の分析、企業・適応症・フェーズ別の各種阻害剤のパイプラインの分析、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション:癌遺伝子阻害剤

第2章 癌遺伝子阻害剤の機序

第3章 世界の癌遺伝子阻害剤市場の概要

  • 現在の市場シナリオ
  • 癌遺伝子阻害剤:臨床パイプラインの分析

第4章 世界の癌遺伝子阻害剤の市場力学

  • 有利な市場指標
  • 商業化における課題

第5章 世界の癌遺伝子阻害剤市場:将来の展望

第6章 癌遺伝子タンパク質阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床
  • 延期・中止

第7章 癌原遺伝子タンパク質c-bcl-2阻害剤のパイプライン:企業・適応症・フェーズ別

  • 研究から承認前まで
  • 上市済み薬の臨床的分析
  • 延期・中止

第8章 癌原遺伝子タンパク質b-raf阻害剤のパイプライン:企業・適応症・フェーズ別

  • 研究から第III相まで
  • 上市済み薬の臨床的分析
  • 延期・中止

第9章 癌原遺伝子タンパク質c-kit阻害剤のパイプライン:企業・適応症・フェーズ別

  • 研究から承認前まで
  • 上市済み薬の臨床的分析
  • 延期・中止

第10章 癌原遺伝子タンパク質c-rel阻害剤のパイプライン:企業・適応症・フェーズ別

  • 研究段階

第11章 癌原遺伝子タンパク質c-akt阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床から第III相まで
  • 延期・中止

第12章 癌原遺伝子タンパク質c-met阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床から第III相まで
  • 上市済み薬の臨床的分析
  • 延期・中止

第13章 癌原遺伝子タンパク質c-ret阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床から第III相まで
  • 上市済み薬の臨床的分析
  • 延期・中止

第14章 癌原遺伝子タンパク質c-mdm2阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床から第I/II相まで
  • 延期・中止

第15章 癌原遺伝子タンパク質阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床段階

第16章 癌原遺伝子タンパク質c-ets阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床段階

第17章 癌原遺伝子タンパク質c-fli-1阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床

第18章 癌原遺伝子タンパク質sc-pim-1阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床から第I/II相まで
  • 延期・中止

第19章 癌原遺伝子タンパク質c-myc阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床から第I/II相まで
  • 上市済み薬の臨床的分析

第20章 癌原遺伝子タンパク質s-c-raf阻害剤のパイプライン:企業・適応症・フェーズ別

  • 延期・中止

第21章 癌原遺伝子タンパク質s-c-myb阻害剤のパイプライン:企業・適応症・フェーズ別

第22章 複数の癌遺伝子阻害剤のパイプライン:企業・適応症・フェーズ別

  • 前臨床から承認済みまで
  • 上市済み薬の臨床的分析
  • 延期・中止

第23章 競合環境

  • AstraZeneca
  • ArQule Inc
  • Biogen Idec
  • Boehringer Ingelheim
  • Celgene Corporation
  • Constellation Pharmaceutical
  • Epizyme Pharmaceutical
  • Genentech
  • GalaxoSmithKline
  • Incyte Corporation
  • Johnson & Johnson
  • Merck
  • Novartis
  • Onyx pharmaceuticals
  • Pfizer

図表一覧

目次

Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the body. Development of such therapeutics is a daunting task because human genome is quite big and consists of variety of genes whose function has yet to be determined by investigators.

Oncogene Inhibitor market is a rapidly growing segment with numerous products at different stages of clinical pipeline and marketed products at different phases of industry life cycle. Pharmaceutical companies are trying to provide efficient medical care to patients and generate significant revenues by their sales. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Several competitors are available for wide range of malignancies which further makes it imperative for them to provide both therapeutic and financial benefit to the patients. Due to which large numbers of pharmaceutical companies are expected to improve their products to achieve higher sales.

Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criteria's set by regulatory authorities. Researchers are trying to develop new formulations to have better safety and efficacy profiles along with minimized side effects. Number of oncogene inhibitor for treatment of different malignancies is increasing every year due to which their market shares are expected to increase several folds in coming years. Escalating competition could be considered as one of the biggest driver for oncogene inhibitor therapeutics because this segment has significantly large number of products.

Different oncogene inhibitors have been successfully commercialized by different pharmaceutical companies in past few decades. Oncogenes like c-met and c-myc are one of the most commonly used targets for inhibitors due their involvement in various cancers. This biological phenomenon has given rise to therapeutics which could be commercialized for different cancer categories. In this way, more revenues could be generated and competition could be offered to other cancer therapeutics due to superior therapeutic efficacy. Ras gene was one of the earliest oncogene identified by investigators known to have proto-oncogenic in nature. However, therapeutic for this gene not available in market due to its complex protein structure that is impregnable by oncogenic inhibitors.

" Oncogene Inhibitors Market & Pipeline Insight 2015" Report Highlight:

  • Global Oncogene Inhibitors Market Overview
  • Oncogene Inhibitors Pipeline by Company, Indication & Phase
  • Oncogene Inhibitors Pipeline: 185 Drugs
  • Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs
  • Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs
  • Proto Oncogene Protein c-akt Inhibitors: 39 Drugs
  • Marketed Oncogene Inhibitors: 22 Drugs
  • Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs

Table of Contents

1. Introduction to Oncogene Inhibitors

2. Mechanism of Oncogene Inhibitors

3. Global Oncogene Inhibitors Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Oncogene Inhibitors Clinical Pipeline Insight

4. Global Oncogene Inhibitor Market Dynamics

  • 4.1 Favorable Market Parameters
  • 4.2 Commercialization Challenges

5. Global Oncogene Inhibitor Market Future Prospects

6. Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase

  • 6.1 Preclinical
  • 6.2 Suspended & Discontinued

7. Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Company, Indication & Phase

  • 7.1 Research till Preregistration
  • 7.2 Marketed Drug Clinical Insight
  • 7.3 Suspended & Discontinued

8. Proto Oncogene Protein b raf Inhibitors Pipeline by Company, Indication & Phase

  • 8.1 Research till Phase-III
  • 8.2 Marketed Drug Clinical Insight
  • 8.3 Suspended & Discontinued

9. Proto Oncogene Protein c-kit Inhibitors Pipeline by Company, Indication & Phase

  • 9.1 Research till Preregistration
  • 9.2 Marketed Drug Clinical Insight
  • 9.3 Suspended & Discontinued

10. Proto-Oncogene Protein c-rel Inhibitors Pipeline by Company, Indication & Phase

  • 10.1 Research

11. Proto Oncogene Protein c-akt Inhibitors Pipeline by Company, Indication & Phase

  • 11.1 Preclinical till Phase-III
  • 11.2 Suspended & Discontinued

12. Proto Oncogene Protein c met Inhibitors Pipeline by Company, Indication & Phase

12.1 Preclinical till Phase-III 12.2 Marketed Drug Clinical Insight 12.3 Suspended & Discontinued

13. Proto Oncogene Protein c ret Inhibitors Pipeline by Company, Indication & Phase

  • 13.1 Preclinical till Phase-III
  • 13.2 Marketed Drug Clinical Insight
  • 13.3 Suspended & Discontinued

14. Proto-Oncogene Protein c mdm2 Inhibitors Pipeline by Company, Indication & Phase

  • 14.1 Preclinical till Phase-I/II
  • 14.2 Suspended & Discontinued

15. Proto-Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase

  • 15.1 Preclinical

16. Proto-Oncogene-Protein-c-ets Inhibitors Pipeline by Company, Indication & Phase

  • 16.1 Preclinical

17. Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline by Company, Indication & Phase

  • 17.1 Preclinical

18. Proto Oncogene Proteins c pim 1 Inhibitors Pipeline by Company, Indication & Phase

  • 18.1 Preclinical till Phase-I/II
  • 18.2 Suspended & Discontinued

19. Proto Oncogene Protein c-myc Inhibitors Pipeline by Company, Indication & Phase

  • 19.1 Preclinical till Phase-I/II
  • 19.2 Marketed Drug Clinical Insight

20. Proto Oncogene Proteins c raf Inhibitors Pipeline by Company, Indication & Phase

  • 20.1 Suspended & Discontinued

21. Proto Oncogene Proteins c myb Inhibitors Pipeline by Company, Indication & Phase

22. Multiple Oncogene Inhibitors Pipeline by Company, Indication & Phase

  • 22.1 Preclinical till Registered
  • 22.2 Marketed Drug Clinical Insight
  • 22.3 Suspended & Discontinued

23. Competitive Landscape

  • 23.1 AstraZeneca
  • 23.2 ArQule Inc
  • 23.3 Biogen Idec
  • 23.4 Boehringer Ingelheim
  • 23.5 Celgene Corporation
  • 23.6 Constellation Pharmaceutical
  • 23.7 Epizyme Pharmaceutical
  • 23.8 Genentech
  • 23.9 GalaxoSmithKline
  • 23.10 Incyte Corporation
  • 23.11 Johnson & Johnson
  • 23.12 Merck
  • 23.13 Novartis
  • 23.14 Onyx pharmaceuticals
  • 23.15 Pfizer

List of Figures and Tables

  • Figure 1-1: Features of Oncogenes
  • Figure 1-2: Types of Genes
  • Figure 1-3:Factors Responsible for Conversion of Proto-Oncogenes to Oncogenes
  • Figure 2-1: Activation of Proto-Oncogenes to Oncogenes
  • Figure 2-2:Benefits of Oncogene Inhibitors
  • Figure 2-3: Mechanism of Crizotinib
  • Figure 2-4: Mechanism of Vemurafenib
  • Figure 2-5: Mechanism of Vorinostat
  • Figure 3-1: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-2: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-3: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-4: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-5: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-6: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-7: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-8: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-9: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-10: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-11: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-12: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-13: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-14: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-17: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-18: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-19: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-20: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-21: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-22: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-23: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-24: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-25: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-26: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-27: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-28: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-29: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-30: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
  • Figure 3-31: Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-32: : Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(Number), 2015
  • Figure 4-1: Oncogene Inhibitor Market Favorable Parameters
  • Figure 4-2: Commercialization Challenges to Oncogene Inhibitors
Back to Top